In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 4, 2012, Pages 429-431

  Krause, Kevin M ^a   Blais, Johanne ^a   Lewis, Stacey R ^a   Lunde, Christopher S ^a   Barriere, Steven L ^a   Friedland, H David ^a   Kitt, Michael M ^a   Benton, Bret M ^a  

^a THERAVANCE INC   (United States)

Author keywords

Gram positive; Hospital acquired pneumonia; HVISA; MRSA; Telavancin

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LINEZOLID; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARRIER STATE; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 84869097168     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.08.010     Document Type: Article

References (20)

1. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Appproved standard - 9th edition. M07-A9 2012, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 22nd Informational supplement (M100-S22) 2012, CLSI, Wayne, PA.
3. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:2383-2388.
4. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008, 62:116-121.
5. Hegde S.S., Difuntorum S., Skinner R., Trumbull J., Krause K.M. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 2009, 63:763-766.
6. Hegde S.S., Skinner R., Lewis S.R., Krause K.M., Blais J., Benton B.M. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J Antimicrob Chemother 2010, 65:725-728.
7. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:1127-1134.
8. Jones R.N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51(Suppl. 1):S81-S87.
9. Klevens R.M., Edwards J.R., Tenover F.C., McDonald L.C., Horan T., Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006, 42:389-391.
10. Leonard S.N., Rybak M.J. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections. Pharmacotherapy 2008, 28:458-468.
11. Leonard S.N., Szeto Y.G., Zolotarev M., Grigoryan I.V. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011, 37:558-561.
12. Lunde C.S., Hartouni S.R., Janc J.W., Mammen M., Humphrey P.P., Benton B.M. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009, 53:3375-3383.
13. Lunde C.S., Rexer C.H., Hartouni S.R., Axt S., Benton B.M. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother 2010, 54:2198-2200.
14. Mendes R.E., Sader H.S., Farrell D.J., Jones R.N. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn Microbiol Infect Dis 2011, 71:93-97.
15. Mendes R.E., Sader H.S., Farrell D.J., Jones R.N. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). Diagn Microbiol Infect Dis 2012, 72:113-117.
16. Pfaller M.A., Mendes R.E., Sader H.S., Jones R.N. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010, 65:2396-2404.
17. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011, 52:31-40.
18. Rybak M.J., Leonard S.N., Rossi K.L., Cheung C.M., Sader H.S., Jones R.N. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46:2950-2954.
19. van Hal S.J., Paterson D.L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010, 55:405-410.
20. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47:399-403.